Clinical trial NCT01943630 (phase 2, status: unknown status)
Conditions: external genital warts
ICD codes: B88.3, S30.845S, S30.846S, S30.845A, S30.845D, S30.846A, S30.846D
Drugs: 15% as101 gel, vehicle
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          1. Women at least 18 years of age and in good health;

          2. Must sign an ethics committee approved informed consent form and be able to adhere to
             study visits and protocol requirements;

          3. Women must agree to avoid sexual contact while the gel is on their skin;

          4. All study participants who are sexually active must use a protection method of
             contraception during treatment and for 60 days after completion of treatment;

          5. Patients with clinical diagnosis of external genital warts, in the external genitalia
             including vulva (labia minora and majora), inguinal folds, pubic area, perineum,
             perianal, or buttocks areas; two or more distinct external genital warts, and wart
             area to be treated that is equal to or less than 10 cm2.

        Exclusion criteria:

          1. Participation in an investigational trial within 30 days prior to screening;

          2. Previous participation in a trial investigating AS101 for any indication;

          3. Topical treatment for genital warts within 14 days of screening;

          4. Cutaneous surgery, including cryosurgery or laser, to genital area within 30 days of
             screening;

          5. Skin irritations of other clinical signs or symptoms associated with prior therapy.

          6. Topical and systemic immunosuppressive or immunomodulatory medications (including
             corticosteroids) within 30 days prior to screening, and while on study;

          7. Current active infection with herpes genitalis or history of herpes genitalis
             infection within the last 30 days prior to screening (patients on long-term
             suppressive antiviral therapy are eligible);

          8. Diagnosis of high-grade cervical dysplasia;

          9. Internal anogenital, vaginal, cervical warts or urethral meatal warts requiring
             treatment;

         10. Chronic or acute skin condition that might interfere with the treatment or evaluation
             of study drug effect;

         11. Screening laboratory tests results from a complete blood count (CBC), chemistry panel
             and urine pregnancy test obtained during screening:

               1. Must be within the site laboratory's defined normal reference ranges, and/or
                  according to the Investigator's decision;

               2. Urine pregnancy test in females of childbearing potential must be negative;

               3. Inadequate renal function: Serum Creatinine >2.0mg/dL (>2.0 ULN);

               4. Inadequate liver function: Serum (total) Bilirubin >2 mg/dl or ALT and/or AST
                  greater than two times the upper limit of the reference range.

         12. Uncontrolled infection or acute severe febrile illness;

         13. Diagnosed as having uncontrolled cardiovascular, hematological, hepatic, neurological,
             renal, endocrine, vascular, autoimmune, or gastrointestinal abnormalities or disease;

         14. Pregnant or lactating;

         15. Known allergy to AS101 or any component of the investigational formulation; or

         16. Subjects with any other clinically significant medical condition, psychiatric
             condition or laboratory abnormality which would, in the judgment of the Investigator,
             interfere with the subject's ability to participate and comply with the trial.